Summary The effect of photodynamic therapy (PDT) on tumour perfusion in both anaplastic (R3327-AT) and well differentiated (R3327-H) Dunning prostatic tumours was studied using the radiopharmaceutical 99Technetium hexamethylpropyleneamine oxime (99"Tc-HMPAO). Tumours in the left flanks of rats (Copenhage x Fischer, F1 hybrids) were treated with interstitial PDT when their volumes reached 2-3 cm3. Qualitative and quantitative data from pre-and post-PDT scintigraphy revealed a light-dose-dependent shut-down of tumour perfusion which was also time-dependent. Maximal shut-down, following a 1,600J light-dose, occurred about 8 h post-PDT. Light exposure 2 h after the intravenous administration of the photosensitiser (Photofrin II) produced a greater vascular shut-down than did light exposure 24 h after the administration of the drug. Regional differences in perfusion within treated and non-treated tumours were measured by tomographic procedures. Light-dose-dependent volumes of perfusion shut-down were demonstrated in addition to the naturally occurring regional differences in tumour perfusion. This radiopharmaceutical may have future utility for monitoring the clinical treatment of solid tumours with PDT.
Photodynamic therapy (PDT) can kill cells by both direct and indirect mechanisms. Direct killing, in vitro, can result from singlet oxygen damage to biomembranes (Bertolini et al., 1984; Grossweiner, 1984) . In particular, damage to lysosomes (Torinuki et al., 1980; Volden et al., 1981; Santus et al., 1983; Reyftmann et al., 1986 ) results in cell autolysis and damage to mitochondria (Sandberg et al., 1982; Burns et al., 1982; Singh et al., 1987) results in disruption of oxidative phosphorylation. Indirect killing, in vivo, can result from microvascular damage causing cessation of blood flow and secondary tumour cell death (Henderson et al., 1985; Selman et al., 1984) .
This research group has previously reported on the potentiation of PDT by misonidazole, a bioreductive cytotoxin, in the treatment of Dunning prostate tumours . Subsequent investigations confirmed this finding for both well differentiated and anaplastic tumours and showed a PDT-dependent binding of tritiated misonidazole to both normal and tumour tissues (Hirsch et al., 1987) . These findings are consistent with PDT-induced tissue hypoxia and subsequent cell killing by adjuvant bioreductive chemotherapy.
If PDT is to become a modality of therapy for solid tumours, non-invasive assays which can measure the extent of PDT-induced vascular shut-down could play a useful role in its development. We therefore undertook a study to investigate PDT-induced vascular shut-down in both well-perfused and poorly-perfused Dunning prostate tumours using scintigraphy with the radiopharmaceutical 99Technetium hexamethylpropyleneamine oxime (9Tc-HMPAO). 99Tc-HMPAO has been shown by Hammersley et al. (1987) to be a good marker of tumour perfusion in experimental tumours and was used by Rowell et al. (1989) to assess blood flow in human lung tumours. This non-invasive technique for monitoring PDT-induced vascular shut-down may have use in the clinic for estimating the extent and kinetics of perfusion shut-down. These parameters would be important for monitoring early treatment response and for scheduling adjuvant bioreductive chemotherapy targeted at naturallyoccurring and induced hypoxia.
Materials and methods

Tumour model
The Dunning prostatic tumour model was initially isolated by Dr W.H. Dunning when it occurred spontaneously in a breeder rat (Dunning, 1963) . Since initial isolation, several sublines have been developed and well characterised (Isaacs, 1987) . The two sublines used in this study, the R3327-H and R3327-AT, represent the extremes of differentiation. The R3327-H tumour obtained from the Papanicolaou Institute (Miami, FL) is well differentiated, hormonally sensitive, diploid and slow growing with a doubling time of 12-20 days. The R3327-AT tumour obtained from Dr D. Coffey of John Hopkins University (Baltimore, MD), is anaplastic, hormonally insensitive, aneuploid, and rapidly growing with a doubling time of 2-3 days.
The tumours were maintained by serial passage in Fl males from matings of Fischer 344 (female) x Copenhagen 2331 (male) rats. The animals were bred by the University of Alberta Health Sciences Laboratory Animal Services from breeder stock obtained from Harlan Spargue, Dawley Inc (Indianapolis, IN) and were cared for in accordance with the guidelines of the Canadian Council on Animal Care. Donor tissue was selected from tumours that had been monitored for growth characteristics and histological appearance (grade) in order to avoid tumour drift. Using aseptic technique, selected tumour pieces of approximately 1 mm3 were implanted surgically into the left flanks of animals greater than 6 weeks of age, as previously described (Thorndyke et al., 1985) . Following grafting, a latency period of 1-2 weeks for the anaplastic tumours and 4-5 months for the well differentiated tumour was observed. Tumour dimensions were measured with calipers in three mutually perpendicular directions while the animals were lightly anesthetised and tumour volumes calculated using the formula V = n/6 x D, x D2 x D3 as described elsewhere (Mador et al., 1982 (Chapman et al., 1991) .
Interstitial phototherapy
The light source used in these experiments was a Coherent CR-599 argon driven dye laser tuned to 630 nm with a maximum output of 4 Watts. The monochromatic light beam was split into eight beams of equal intensity and directed down 600 micron quartz optical fibres with 1.5 cm cylindrical diffusing tips 
Results
This study yielded both qualitative and quantitative data on PDT-induced vascular shut-down. Figure Ia There is virtually no perfusion to the tumour and perfusion to the surrounding normal tissue is also diminished. Likewise, Figure 2a is a pre-PDT scintigram of a rat bearing the anaplastic R3327-AT tumour in its left flank. This tumour is less well perfused relative to the R3327-H tumour. Figure 2b is a post-PDT scintigram of the same animal 1 h following PDT at 1,600 J. Again there is a perfusion deficit involving the treated tumour and surrounding normal tissue.
Quantitative data was obtained using the ROI program. Figure 3a and 3b demonstrate ROIs in which activities were measured to estimate perfusion of R3327-AT and R3327-H tumours, respectively. These tumour/brain ratios show that the well differentiated tumour, on average, is 1.77 x better perfused than the anaplastic tumour (Table I) . Quantitative analyses of pre-and post-PDT scintigrams demonstrate a light-dose and time-dependent vascular shut-down for both the R3327-H and R3327-AT tumours. Figure 4 shows the light-dose-dependency of vascular shut-down to be similar for both tumours. Data points have been normalised to pretreatment perfusion levels which are significantly different for the two tumours (Table I) . Light-dose-dependent vascular shut-down and tumour response in the R3327-AT tumour appear to correlate (Table II) .
The temporal relationship of vascular shut-down was studied using both anaplastic and well differentiated tumours. Tomographic studies were performed with anaplastic tumours whose volumes were approximately 4cm3 so that boundaries and regional differences in vascular perfusion could be observed. A control tumour, receiving interstitial light only (no PIT), was included in each study. Both animals were treated with 2,400 J and received an equal dose of the radiopharmaceutical 99mTc-HMPAO (prepared from the same kit) 1 h post-PDT. Figure 6a shows intratumour distributions of radioactivity in a treated tumour (upper two rows) and in a control tumour (lower two rows). In the treated tumour a region of perfused tissue surrounds that adjacent to the illuminators and probably represents the limit of 'effective' 630 nm light exposure. Perfusion was lower in the periphery of the lased tumour compared to the non-lased tumour and this effect would become amplified at longer times, similar to results shown in Figure 5 . Therefore a seven fibre icosohedral array with a 8 mm spacing will be limited to treating tumours of 2 -3 cm3 with attenuation and perfusion properties similar to the R3327-AT tumour. Indeed, if 991Tc-HMPAO perfusion can be considered a marker of biologically effective light penetration, then the regional limitation of perfusion shut-down should relate to the isodose plots of this tumour as shown in Figure 6b . The black line forming the ellipsoid around the isodose plots represents the tumour boundary as measured with calipers. The minimum dose required to produce acute vascular shut-down (1 h post-PDT) appears to correspond with the 35 J cm-2 isodose line which is about 3 mm from the surface of each illuminator.
Since these studies were designed to measure vascular damage, we administered the light-dose 2 h following administration of PIT when the drug concentration is maximal in the blood pool as demonstrated by Paramsothy et al. (1989) . Clinical phototherapy however, is normally applied 24-72 h after photosensitiser administration in an attempt to exploit maximum tumour/normal tissue ratio of photosensitiser. We therefore, also measured vascular shut-down when phototherapy was applied 24 h following administration of PII. Perfusion shut-down with phototherapy at 2 h was, on average, 35% greater than that observed at 24 h following administration of PII (Table III) . This difference in perfusion shut-down was significantly different for the two groups (Student's t-test, 0.02).
Discussion
Tumours with two extremes of tumour differentiation were chosen for these experiments because of their different proliferation kinetics and inherent perfusion which might influence PDT response. Previous experiments had shown that the R3327-AT tumour is more resistant to ionising radiation than its well differentiated counterpart, the R3327-H tumour (Mador et al., 1982; Thorndyke et al., 1985) . The increased radioresistance of the R3327-AT tumour was attributed to a 15-25% hypoxic fraction, demonstrated by '4C-Misonidazole labelling. Little or no hypoxia was observed in well differentiated tumours of up to 3 cm3 with this hypoxic marker (Thorndyke et al., 1985) .
In this current study, comparison of tumour/brain ratios of the perfusion radiopharmaceutical, 99mTc-HMPAO, revealed that the well differentiated tumour on average is 1.77 x better perfused than the anaplastic tumour. Since PDT is also dependent on oxygen for cell killing (Moan et al., 1985; Mitchell et al., 1985) it might be hypothesised that the anaplastic tumour would be more resistant to PDT. In fact, previous studies by Hirsch et al. (1987) had shown the R3327-H tumours to respond better to PDT than did the R3327-AT tumour at equal photofrin and light-doses. Our measurements of perfusion shut-down have failed to demonstrate a measurable difference in tumour response to PDT.
Both tumour sublines displayed a similar fractional shutdown of perfusion as a function of light-dose and time.
The tomographic studies showed that the penetration of (effective' light required to produce acute vascular shut-down after a total dose of 2,400 J is limited to tumour zones within 3 mm from each illuminator. When compared with the light dosimetry, this zone of perfusion shut-down corresponds to a threshold dose of about 35 J cm-2. The light-doses delivered to the effected tumour tissue boundary ranged from 100 to 35 J cm2 as a consequence of the rapid fall off in light intensity resulting from spacial dilution and tissue attenuation, as well as, the limited resolution of the assay. Other factors which can contribute to the heterogeneity of this biological effect are non-uniform PII distribution and variable tissue oxygenation resulting from regional differences in tumour perfusion. Our produce permanent vascular collapse with a PII dose of 10 mg kg-'. Hilf et al. (1987) using 31P-NMR and Star et al.
(1986) using sandwich observation chambers have reported higher values of 54Jcm-2 and 72 J cm2, respectively, to produce permanent vascular changes. This experimental agreement on 'effective' light-dose for PDT response is surprisingly good when one considers that diverse biological systems, with differing vascularisation, were utilised in the different studies. . released by PDT (Fingar et al., 1990; Henderson et al., 1989) .
Whatever the cause of this moderate tumour ischemia, it could become a target for bioreductive chemotherapy for potentiation of PDT response Henry et al., 1989 The solid black line surrounding the isodose plots represents the tumour boundary. 
Conclusion
Our observations are consistent with other studies investigating vascular effects of PDT using different techniques such as: radiolabelled microspheres (Selman et al., 1984) , sandwich observation chambers (Star et al., 1986) , NMR spectroscopy (Hilf et al., 1987) and dye exclusion (Fingar et al., 1987) . Together these studies demonstrate that infarction is an early, dose-dependent phenomenon that occurs in both welland poorly-differentiated tumours, as well as, in normal tissue and probably accounts for the majority of tumour cell 
